Related Experiment Video

Updated: Feb 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K

Targeting ORM1-CCR5 axis inhibits the aggressive phenotype of synovial fibroblasts and alleviates RA

Min Liu1, Yutong Chen2, Xuyang Ding2

  • 1Department of Traditional Chinese Medicine, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang, China.

Open Medicine (Warsaw, Poland)
|February 23, 2026
PubMed
Abstract

Insights

Orosomucoid 1 (ORM1) deficiency suppresses rheumatoid arthritis (RA) progression by downregulating C-C chemokine receptor 5 (CCR5). This finding offers a new therapeutic target for RA treatment.

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction.
  • Fibroblast-like synoviocytes (FLS) play a crucial role in RA pathogenesis.
  • The specific molecular mechanisms driving RA progression require further elucidation.

Purpose of the Study:

  • To investigate the role of orosomucoid 1 (ORM1) in rheumatoid arthritis (RA).
  • To explore the relationship between ORM1 and C-C chemokine receptor 5 (CCR5) in RA.
  • To evaluate the therapeutic potential of targeting the ORM1-CCR5 axis in RA.

Main Methods:

  • Bioinformatic analysis of gene expression datasets (GSE15573).
  • In vitro studies using collagen-II stimulated RA FLS to assess ORM1 and CCR5 expression and interaction.
  • In vivo studies using a collagen-induced arthritis (CIA) rat model with ORM1 or CCR5 knockdown.

Main Results:

  • ORM1 and CCR5 were upregulated in stimulated FLS and CIA rat synovial tissues.
  • ORM1 positively regulated CCR5 expression, and they interacted within FLS.
  • ORM1 or CCR5 inhibition reduced FLS viability, migration, and invasion, and alleviated arthritis symptoms in CIA rats.

Conclusions:

  • ORM1 promotes RA progression by enhancing FLS aggressive phenotype via CCR5.
  • Targeting ORM1 or CCR5 demonstrates therapeutic potential for RA.
  • ORM1 deficiency suppresses RA progression by downregulating CCR5.
Keywords:
C-C chemokine receptor 5fibroblast-like synoviocytesorosomucoid 1rheumatoid arthritissynovial hyperplasia

More Related Videos

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue09:18

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue

Published on: February 24, 2023

10.5K
Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model12:23

Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model

Published on: April 24, 2020

21.2K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K